Jul 12, 2013, 08.09 PM | Source: CNBC-TV18
US trade representative Michael Froman in a meeting with Indian commerce minister Anand Sharma today raised concerns about Intellectual Property Rights (IPR) climate in India.
Froman made indirect references to the developments regarding the Novartis as ell as the Bayer case. In April Supreme Court had rejected Swiss pharma firm Novartis' patent plea for Glivec. While in case of Bayer, IPAB had ruled in March that the Indian government was within its rights in issuing a compulsory licence allowing the manufacture of affordable generic versions of Bayer’s patented drug.
Froman also raised concern about preferential treatment given to indigenous IPR in India and claimed that treatment favoured domestic manufacturers, suppliers.
He also told Sharma that it was possible to promote access to medicines without stifling innovation. He appreciated India's move to put the preferential market access for electronic goods. He also discussed India's concerns regarding the Immigration Bill. It remains to be seen if all this dialogue that happened today will lead into any concrete moves as far as the US Immigration Bill is concerned.
India to evolve into more stable investment destination: KPMG
Govt to take Search Committee route to find Oil India head
OIL will be the second large public sector unit to
Aus keen to invest in India's LNG, health, financial sectors
Auto exports from India decline 19% in January
million to Algeria. Besides, PVs worth USD 158 mil
Make in India Week: India, Sweden decide to step up ties
Make in India fostering competitive federalism: Fadnavis